Definium Therapeutics, Inc. 4

Matthew T. Wiley, Chief Commercial Officer of Definium Therapeutics, Inc., received 125,000 common shares as a performance share unit vesting award, increasing his direct holdings to 362,133 shares.

On September 14, 2026, Matthew T. Wiley, Chief Commercial Officer of Definium Therapeutics, Inc., acquired 125,000 common shares at a stated transaction price of $0.00 per share, reflecting the third tranche vesting under a performance share unit award that was originally granted on March 17, 2025. These shares remain subject to continued employment-based vesting conditions through March 17, 2028 and were issued upon achievement of specified clinical and regulatory milestones. Following this award, Wiley’s direct beneficial ownership increased to 362,133 common shares of Definium Therapeutics, Inc. The transaction is best characterized as a performance-based equity award/RSU vesting rather than an open-market purchase or sale, and no explicit market price was provided to calculate the dollar value; as such, the economic value is inferred to be compensation-related rather than a discretionary trade.

Filing Facts

CIK

1813814

Ticker

DFTX

Form

4

Source Type

fda

Accession

0001193125-26-389890

Alert Tier

5